Equibles does not estimate personal net worth.
Get an email with a short summary when Palvella Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get PVLA alertsWes Koppinen is recorded as CEO at Palvella Therapeutics, Inc. (PVLA). Wes Koppinen has spoken on 2 earnings calls and 2 other investor events across 1 company, most recently for Palvella Therapeutics, Inc. on November 5, 2026. Palvella Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Palvella Therapeutics, Inc. includes Wesley H. Kaupinen (CEO and Board Member), George M. Jenkins (Chairman and Board Member), James Geraghty (Chairman) and 7 others.
“Good morning, everyone, and thank you all for joining us on the Pauvela Therapeutics third quarter earnings call and corporate update. For children and adults living with microcystic lymphatic malformations, every day counts.”
“Appreciate you and Andrew on the H.C. Wainwright hosting Palvella today and the great research coverage you've provided us since we went public. I'm going to start with the name Paul Vella.”
“The second quarter marked the culmination of many years of work to pioneer and accelerate the development of cutorin rapamycin through two successful clinical studies in microcystic lymphatic malformations, a serious, rare, chronically debilitating lifelong genetic disease for which there are no FDA-approved therapies.”
“Well, thank you, Elizabeth, for having me today at the Goldman Conference. I'd like to start with the name Paul Vela. Paul Vela in Finnish means to serve. So the mission of our company is to serve patients that have serious rare skin diseases and vascular malformations that currently have no FDA-approved therapies.”
Biotechnology · Healthcare
CEO
